PLIANT THERAPEUTICS, INC. (PLRX) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	S-1/A
Revenues	9.7	7.6	41.8	57.1	-24.4
Revenue growth	27.9%	-81.9%	-26.7%	-333.7%
Cost of goods sold	0.0	0.0	0.0	0.0	-92.7
Gross profit	9.7	7.6	41.8	57.1	68.3
Gross margin	100.0%	100.0%	100.0%	100.0%	-279.9%
Selling, general and administrative [+]	39.9	27.6	17.3	10.9	6.5
General and administrative	39.9	27.6	17.3	10.9	6.5
Research and development	96.9	77.5	66.2	47.4
Other operating expenses					92.7
EBITDA [+]	-125.4	-96.0	-40.3	-0.1	-30.2
EBITDA growth	30.6%	138.0%	34082.2%	-99.6%
EBITDA margin	-1294.5%	-1267.8%	-96.5%	-0.2%	123.9%
Depreciation and amortization	1.8	1.5	1.3	1.1	0.7
EBIT [+]	-127.2	-97.5	-41.6	-1.2	-30.9
EBIT growth	30.4%	134.2%	3283.0%	-96.0%
EBIT margin	-1313.4%	-1288.1%	-99.6%	-2.2%	126.6%
Interest income					0.7
Interest income					0.7
Other income (expense), net	3.9	0.3	0.1	0.6	0.0
Pre-tax income	-123.3	-97.3	-41.5	-0.6	-30.3
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-123.3	-97.3	-41.5	-6.9	0.0
Net margin	-1273.3%	-1284.5%	-99.3%	-12.0%	0.1%

Basic EPS [+]	($2.94)	($2.71)	($1.95)	($4.22)	($30.16)
Growth	8.2%	39.4%	-53.9%	-86.0%
Diluted EPS [+]	($2.94)	($2.71)	($1.95)	($4.22)	($30.16)
Growth	8.2%	39.4%	-53.9%	-86.0%


Shares outstanding (basic) [+]	42.0	35.8	21.3	1.6	0.0
Growth	17.2%	67.9%	1214.8%	139189.8%
Shares outstanding (diluted) [+]	42.0	35.8	21.3	1.6	0.0
Growth	17.2%	67.9%	1214.8%	139189.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.